– USA, CA – Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company, today announced the appointment of Lisa Rometty to its Board of Directors, bringing significant global commercial leadership experience across a spectrum of start-ups to mature businesses in the medical device, technology, and pharmaceuticals.
“In our effort to pioneer the field of oral biologics, we are building a world-class team that can help us achieve our goals. I’m delighted to welcome Lisa to our Board. Lisa’s expertise in commercializing new products and forming strategic partnerships will play a critical role in the ongoing development of the RaniPill technology and its anticipated future commercialization,” said CEO, Talat Imran.
About Lisa Rometty
Lisa Rometty is a seasoned healthcare executive with more than 25 years of experience in global commercialization, strategic partnerships, product development, and marketing. She has led large global teams in China, Southeast Asia, Japan, Europe, and the US, and her expertise includes leading operations within highly complex and regulated environments; commercializing new products and services; pioneering new customer experiences, and creating new ecosystems via partnerships and mergers and acquisitions.
Ms. Rometty currently serves as President of CVS Kidney Care, a CVS Health start-up that is focused on disrupting the kidney disease market through patient-centric technology. Before her role at CVS Health, Ms. Rometty served as President, Global Client Solutions at Syneos Health. Before Syneos, she held roles as Chief Commercial Officer and General Manager, Oncology & Life Sciences at IBM Watson Health Solutions. Earlier in her career, Ms. Rometty held leadership roles with Baxter Healthcare and General Electric.
“I’ve spent my career working to improve patients’ lives. Rani offers an incredible opportunity to transform how people are treated with life-saving biologic therapies. I could not be more excited to join Rani’s board to help lay the groundwork for the potential commercialization of the novel RaniPill technology,” said Lisa Rometty.
Ms. Rometty earned an MBA from the University of Notre Dame and a BS in Social Science & International Business from Michigan State University.
About Rani Therapeutics
Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics. Rani has developed the RaniPill capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection of biologics with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability, and bioavailability using the RaniPill capsule.
For more information: https://www.ranitherapeutics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.